Plain-language summary
Meta-analytic risk assessment pooling β-alanine trials to evaluate adverse events alongside efficacy. The headline finding: at typical loading doses the safety profile is benign, with paresthesia the most consistent — and benign — observation.
Key takeaways
- ›Favorable safety profile at standard doses.
- ›Efficacy holds in pooled performance endpoints.
- ›Useful for regulators and formulators.
About this summary
The summary and key takeaways above are written by our editorial team in plain language for general readers. They are not the original abstract. For the authors' own wording, methodology, statistics, and full reference list, follow the source link to the published record.